Clinical trials: Raynaud's Disease
Raynaud Disease, Scleroderma, Systemic
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
The aim of the study is to determine if postocclusive hyperemia of palmar and dorsal face of the hand with Laser speckle contrast imaging discriminate between patients with systemic sclerosis, subjects with primary Raynaud's…
- Trial name
- SPECIES (NCT01743612)
- Testing
- laser speckle contrast imaging, Cooling
- Where
- 2 sites in France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Raynaud Disease
Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.
- Trial name
- NCT00251238
- Testing
- Ginkgo biloba extract EGb 761
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- VSM Geneesmiddelen b.v.
Raynaud Phenomenon, Raynaud Disease
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
The purpose of this study is to analyze the effects of an intervention with galvanic electrical current on the number of attacks , temperature, pain, peripheral blow flow and upper limb functionality in patients with Raynaud's…
- Trial name
- NCT03699436
- Testing
- Electrotherapy with Galvanic Current, Control without Electric Stimulation Therapy
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Universidad de Granada
Raynaud Disease, Hyperemia
PORH and Response to Cold in Raynaud's Phenomenon.
The main objective of the study is to determine if implication of epoxy-eicosatriénoïc acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by…
- Conditions
- Raynaud Disease, Hyperemia, Cold
- Trial name
- REFRAIN (NCT02183779)
- Testing
- post-occlusive hyperemia, cooling box, L-NMMA and Fluconazole dermic injection
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Systemic Sclerosis, Raynaud Phenomenon
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
The goal of this observational pilot data acquisition study is to establish if target users can obtain diagnostic quality images in the clinic, from participants with Systemic Sclerosis (SSc), and SSc spectrum conditions.
- Trial name
- NCT06291142
- Testing
- Observation - Nailfold capillaroscopy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Skin Cancer, Skin Diseases
Multi-modal Quantitative Imaging of the Skin
This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.
- Conditions
- Skin Cancer, Skin Diseases, Atopic Dermatitis, Psoriasis
- Trial name
- DermaFlow (NCT06989216)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Raynaud Phenomenon, Systemic Sclerosis
Cold Challenge With C21 in RP
This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis.
- Trial name
- NCT04388176
- Testing
- C21
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Vicore Pharma AB
Raynaud's Phenomenon, Digital Ulcers
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity and adversely affects the quality of life.
- Conditions
- Raynaud's Phenomenon, Digital Ulcers, Scleroderma
- Trial name
- NCT01117298
- Testing
- Tadalafil
- Where
- 4 sites in India
- Volunteers
- 66 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Raynaud's Phenomenon, Skin Necrosis
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.
- Trial name
- Anti-Vasospasm (NCT01378845)
- Testing
- Tracleer, Prostavasin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Christoph Hehrlein
Raynaud's Disease, Raynaud Phenomena
Open Label Treprostinil Raynaud's Study
Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed.
- Conditions
- Raynaud's Disease, Raynaud Phenomena, Raynauds
- Trial name
- NCT07112183
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for…
- Trial name
- NCT04915950
- Testing
- Temanogrel
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pfizer
Raynaud Phenomenon, Primary Raynaud Phenomenon
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of…
- Conditions
- Raynaud Phenomenon, Primary Raynaud Phenomenon, Raynaud Disease, Raynaud Syndrome
- Trial name
- NCT03869008
- Testing
- gammaCore Sapphire
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Raynaud's Disease
Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.
Patients presenting to UIC rheumatology clinic with Raynaud's disorder and scleroderma will be asked to participate. 10 hands of patients with both Raynaud's disorder and scleroderma will be studied.
- Trial name
- NCT02615964
- Testing
- Nova Flow Procedure
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Systemic Sclerosis
CSL Behring Sclero XIII
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold)…
- Trial name
- NCT02551042
- Testing
- Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College, London
Raynaud
Tadalafil for the Treatment of Raynaud's
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
- Trial name
- NCT00822354
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
Microstomia, Scleroderma
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
The principal objective is to measure the degree to which oral microstomia caused by sclerosing skin disease improves after treating patients with local hyaluronidase injections.
- Conditions
- Microstomia, Scleroderma, CREST Syndrome, Scleromyxedema
- Trial name
- NCT04656704
- Testing
- hyaluronidase injected intradermally
- Sponsor
- Brigham and Women's Hospital
Raynaud Disease, Raynaud Disease Secondary to Scleroderma
Lab Study of MQX-503 in Treatment of Raynaud's
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin…
- Conditions
- Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
- Trial name
- NCT00253331
- Testing
- topical organogel with nitroglycerin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- MediQuest Therapeutics